Stock DEVA DEVA HOLDING
Add to a list
To use this feature you must be a member
Log inSign up

Financials Deva Holding

Equities

DEVA

TRADEVAW91E2

Pharmaceuticals

Delayed Borsa Istanbul
Other stock markets
 08:24:09 2024-06-11 am EDT 		5-day change 1st Jan Change
87.7 TRY -1.02% Intraday chart for Deva Holding -10.24% +16.08%
May. 17 Deva Holding A.S. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 12 Tod's rises 17% on L Catterton bids to help owner's delisting plan RE

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 658.1 1,798 4,828 5,749 13,841 15,111
Enterprise Value (EV) 1 1,265 2,321 5,313 6,172 15,904 17,036
P/E ratio 4.84 x 6.29 x 7.41 x 4.91 x 10.2 x 4.46 x
Yield - 1.11% 0.41% 0.52% 0.22% -
Capitalization / Revenue 0.63 x 1.31 x 2.59 x 2.47 x 3.09 x 1.33 x
EV / Revenue 1.22 x 1.69 x 2.85 x 2.65 x 3.55 x 1.5 x
EV / EBITDA 4.42 x 5.3 x 7.8 x 6.84 x 11.9 x 10.6 x
EV / FCF -4.03 x -54.5 x -17.6 x -10.3 x -7.42 x -7.28 x
FCF Yield -24.8% -1.84% -5.67% -9.67% -13.5% -13.7%
Price to Book 0.88 x 1.74 x 2.95 x 2.11 x 3.52 x 1.02 x
Nbr of stocks (in thousands) 200,019 200,019 200,019 200,019 200,019 200,019
Reference price 2 3.290 8.990 24.14 28.74 69.20 75.55
Announcement Date 3/8/19 3/6/20 3/5/21 3/4/22 3/10/23 5/17/24
1TRY in Million2TRY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,041 1,374 1,863 2,330 4,478 11,330
EBITDA 1 285.9 438.1 680.8 901.9 1,340 1,614
EBIT 1 251 399.9 633.3 841.1 1,256 1,101
Operating Margin 24.12% 29.1% 33.99% 36.09% 28.05% 9.71%
Earnings before Tax (EBT) 1 156 280.7 646.5 1,158 1,300 1,976
Net income 1 136.4 286 651.4 1,170 1,360 3,385
Net margin 13.1% 20.82% 34.96% 50.21% 30.38% 29.88%
EPS 2 0.6800 1.430 3.257 5.850 6.800 16.93
Free Cash Flow 1 -313.5 -42.59 -301.3 -597.1 -2,142 -2,342
FCF margin -30.12% -3.1% -16.17% -25.62% -47.84% -20.67%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - 0.1000 0.1000 0.1500 0.1500 -
Announcement Date 3/8/19 3/6/20 3/5/21 3/4/22 3/10/23 5/17/24
1TRY in Million2TRY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 606 523 484 423 2,063 1,924
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.121 x 1.193 x 0.7113 x 0.4692 x 1.539 x 1.192 x
Free Cash Flow 1 -313 -42.6 -301 -597 -2,142 -2,342
ROE (net income / shareholders' equity) 20.2% 32.2% 48.9% 53.6% 40.8% 25.7%
ROA (Net income/ Total Assets) 10.7% 13.2% 15.2% 12.9% 11.5% 3.2%
Assets 1 1,271 2,167 4,285 9,090 11,872 105,755
Book Value Per Share 2 3.730 5.150 8.170 13.60 19.70 73.90
Cash Flow per Share 2 0.6100 1.390 3.050 6.550 3.010 7.580
Capex 1 69.8 147 268 337 755 529
Capex / Sales 6.7% 10.72% 14.38% 14.46% 16.87% 4.67%
Announcement Date 3/8/19 3/6/20 3/5/21 3/4/22 3/10/23 5/17/24
1TRY in Million2TRY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
DEVA HOLDING Stock Deva Holding
+16.08% 547M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+48.39% 779B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.35% 631B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.13% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.61% 333B
ABBVIE INC. Stock AbbVie Inc.
+10.00% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.75% 249B
ROCHE HOLDING AG Stock Roche Holding AG
-1.72% 216B
NOVARTIS AG Stock Novartis AG
+11.05% 214B
AMGEN INC. Stock Amgen Inc.
+5.80% 163B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. DEVA Stock
  4. Financials Deva Holding